# US 2022/0009938 A1 · 11,13-modified saxitoxins for the treatment of pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009938 A1
- Document ID: US20220009938A1
- Status: Published application
- Kind: A1
- Application number: 17/282,744
- Filed: 2019-10-03
- Published: 2022-01-13
- Earliest claimed: 2018-10-03
- Assignees: Siteone Therapeutics, Inc.
- Applicants: Siteone Therapeutics, Inc.
- Inventors: Hassan PAJOUHESH; Xiang ZHOU; John MULCAHY
- Web page: https://patentgrep.com/patent/US20220009938A1

## CPC

- C07D 487/14: Ortho-condensed systems
- C07D 487/20: Spiro-condensed systems
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

## Claims

### Claim 1

A compound of Formula (I):
wherein
R1 is —NR3aR3, —NR4C(O)R4a, heteroaryl, —CH2NH2, —CH2CH2NH2, —CH2NH3+, —CH2CH2NH3+, —NR5S(O)2R5a, —NR6C(O)NR6aR6b, or —NR8C(O)OR8a;
R2 is —NR7C(O)R7a;
R3 is hydrogen or C1-6alkyl;
R3a is hydrogen or C1-6alkyl;
R4 is hydrogen or C1-6alkyl;
R4a is hydrogen; C1-6alkyl; halo-C1-6alkyl; amino-C1-6alkyl; C1-6alkylaminoC1-6alkyl;
di-C1-6alkylaminoC1-6alkyl; C1-6alkoxyC1-6alkyl; cycloalkyl; cycloalkylalkyl; aryl optionally substituted with 1, 2, 3, or 4 R4b groups; aralkyl where the aryl portion is optionally substituted with 1, 2, 3, or 4 R4b groups; heterocycloalkyl optionally substituted with 1, 2, 3, or 4 R4b groups; heteroaryl optionally substituted with 1, 2, 3, or 4 R4b groups; heteroaralkyl where the heteroaryl portion is optionally substituted with 1, 2, 3, or 4 R4b groups; heterocyclic optionally substituted with 1, 2, 3, or 4 R4b groups; or heterocyclicalkyl optionally substituted with 1, 2, 3, or 4 R4b groups;
each R4b, when present, is independently C1-6alkyl, hydroxy, halo, halo-C1-6alkyl, hydroxy-C1-6alkyl, C1-6alkoxy, cyano, phenyl, or —O—(C1-6alkylene)-OZ, wherein Z is hydrogen or
wherein Y is hydrogen or Boc group, and represents the point of attachment;
R5 is hydrogen or C1-6alkyl;
R5a is heterocycloalkyl, amino, C1-6alkylamino, or di-C1-6alkylamino;
R6 is hydrogen or C1-6alkyl;
R6a is hydrogen, or C1-6alkyl;
R6b is hydrogen, C1-6alkyl, C1-6alkoxy or cycloalkyl;
R8 is hydrogen or C1-6alkyl;
R5a is hydrogen, C1-6alkyl, cycloalkyl or phenyl;
R7 is hydrogen or C1-6alkyl;
R7a is aryl optionally substituted with 1, 2, 3, or 4 R7h; heterocyclic optionally substituted with 1, 2, 3, or 4 R7b; or biphenyl optionally substituted with 1, 2, 3, or 4 R7b; and
each R7b, when present, is independently halo, C1-6alkyl, halo-C1-6alkyl, aryl-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, aryloxy, nitro, C1-6alkylthio, halo-C1-6alkylthio, C1-6alkylsulfinyl, halo-C1-6alkylsulfinyl, C1-6alkylsulfonyl, halo-C1-6alkylsulfonyl, amino, C1-6alkylamino, di-C1-6alkylamino, —C(O)(heterocycloalkyl), phenyl, or cyano; where the aryl in aryloxy and aryl-C1-6alkyl are optionally substituted with 1, 2, or 3 groups independently selected from C1-6alkyl, halo, and halo-C1-6alkyl; or
a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, or combinations thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is according to Formula (Ia):
a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, or combinations thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein the compound is according to Formula (Ib):
a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, or combinations thereof.

### Claim 4 (depends on 1, 2, 3)

The compound of anyone of claims 1-3, wherein R1 is —NR4C(O)R4a, or —NR8C(O)OR8a.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein R1 is —NR4C(O)R4a.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R4 is hydrogen.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R4a is hydrogen; C1-6alkyl; halo-C1-6alkyl; amino-C1-6alkyl; C1-6alkoxyC1-6alkyl; cycloalkyl; cycloalkylalkyl; aryl optionally substituted with 1, 2, 3, or 4 R4b groups; aralkyl where the aryl portion is optionally substituted with 1, 2, 3, or 4 R4b groups; heterocycloalkyl optionally substituted with 1, 2, 3, or 4 R4b groups; heterocyclic optionally substituted with 1, 2, 3, or 4 R4b groups; or heteroaryl optionally substituted with 1, 2, 3, or 4 R4b groups.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is heterocycloalkyl optionally substituted with 1, 2, 3, or 4 R4b groups.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R4a is unsubstituted heterocycloalkyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is heterocyclic optionally substituted with 1, 2, 3, or 4 R4b groups.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 10)

The compound of any one of claims 1-7 and 10, wherein R4a is heterocyclic substituted with 1, 2, or 3 halo groups which are independently selected from F, Cl, Br and I.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is heteroaryl optionally substituted with 1, 2, 3, or 4 R4b groups.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 12)

The compound of any one of claims 1-7 and 12, wherein R4a is selected from the group consisting of
and wherein R4a is optionally substituted with 1, 2, 3, or 4 R4b groups.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 12)

The compound of any one of claims 1-7, 12, and 13, wherein R4a is unsubstituted heteroaryl or is heteroaryl substituted with one or two R4b groups independently selected from the group consisting of alkyl, hydroxy, alkoxy, halo, and —O—(C1-6alkylene)-OH.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is aryl optionally substituted with 1, 2, 3 or 4 R4b groups.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is phenyl optionally substituted with 1, 2, 3 or 4 R4b groups.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 15)

The compound of any one of claims 1-7, 15, and 16, wherein R4a is phenyl optionally substituted with one or two R4b groups independently selected from the group consisting of halo, hydroxy, and —O—(C1-6alkylene)-OH.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is hydrogen.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is C1-6alkyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a halo-C1-6alkyl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is amino-C1-6alkyl; C1-6alkylaminoC1-6alkyl; or di-C1-6alkylaminoC1-6alkyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is C1-6alkoxyC1-6alkyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is cycloalkyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is cycloalkylalkyl.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R4a is aralkyl where the aryl portion is optionally substituted with 1, 2, 3, or 4 R4b.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 15, 16)

The compound of any one of claims 1-8, 10, 12, 13, 15, 16, and 25, wherein each R4b, when present, is independently C1-6alkyl, halo, halo-C1-6alkyl, hydroxy-C1-6alkyl, C1-6alkoxy, or —O—(C1-6alkylene)-OZ, wherein Z is hydrogen or
wherein Y is hydrogen or Boc group, and represents the point of attachment.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 15, 16)

The compound of any one of claims 1-8, 10, 12, 13, 15, 16, and 25, wherein each R4b, when present, is independently cyano, or phenyl.

### Claim 28 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R1 is —NR3aR3, heteroaryl, —CH2NH2, or —CH2NH3+.

### Claim 29 (depends on 1, 2, 3, 28)

The compound of any one of claims 1-3 and 28, wherein R3a and R3 are both C1-6alkyl; or R3a and R3 are both hydrogen.

### Claim 30 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R1 is —NR5S(O)2R5a.

### Claim 31 (depends on 1, 2, 3, 30)

The compound of any one of claims 1-3 and 30, wherein R5 is hydrogen and R5a is heterocycloalkyl.

### Claim 32 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R1 is —NR6C(O)NR6aR6b.

### Claim 33 (depends on 1, 2, 3, 32)

The compound of any one of claims 1-3 and 32 wherein R6 is hydrogen.

### Claim 34 (depends on 1, 2, 3, 32, 33)

The compound of any one of claims 1-3 and 32-33, wherein R6a is C1-6alkyl and R6b is C1-6alkoxy; R6a is hydrogen and R6b is cycloalkyl; or R6a and R6b are both C1-6alkyl.

### Claim 35 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein R1 is —NR8C(O)OR8a.

### Claim 36 (depends on 1, 2, 3, 4, 35)

The compound of any one of claims 1-4 and 35, wherein R8 is hydrogen and Rga is C1-6alkyl.

### Claim 37 (depends on 1, 2, 3, 4, 35)

The compound of any one of claims 1-4 and 35, wherein R1 is hydrogen and R8a is C1-6alkyl, cycloalkyl or phenyl.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, wherein R7 is hydrogen.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38 wherein R7a is heterocyclic optionally substituted with 1, 2, 3, or 4 R7b.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39 wherein the heterocyclic in R7a is benzo-1,4-dioxanyl, benzodioxolyl, 2,3-dihydrobenzofuranyl, chromanyl,
or 2,2-dioxo-1,3-dihydrobenzo[c]thienyl; each of which is optionally substituted with 1, 2, or 3 groups independently selected from halo, C1-6alkyl, halo-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, and phenyl.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, wherein R7a is unsubstituted
unsubstituted
unsubstituted
unsubstituted
or unsubstituted 2,2-dioxo-1,3-dihydrobenzo[c]thienyl.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39 wherein the heterocyclic in R7a comprises one heteroatom which is oxygen and wherein the heterocyclic is optionally substituted with 1, 2, or 3 groups independently selected from halo, C1-6alkyl, halo-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, and phenyl.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, wherein the heterocyclic in R7a comprises one heteroatom which is oxygen and wherein the heterocyclic is optionally substituted with one gem-di-C1-3alkyl or one gem-dihalo.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, wherein the heterocyclic in R7a is benzo-1,4-dioxanyl optionally substituted with one gem-di-C1-3alkyl, cyclopropyl, or one gem-dihalo.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, wherein R7a is

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein R7a is aryl optionally substituted with 1, 2, 3, or 4 R7b.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 46)

The compound of any one of claims 1-38 and 46, where the aryl in R7a is phenyl, naphthyl, tetrahydronaphthyl, fluorenyl, 6,7,8,9-tetrahydro-5H-benzo[7]annulenyl,
or indanyl; each of which is optionally substituted with 1, 2, or 3 groups independently selected from halo, C1-6alkyl, halo-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, C1-6alkylthio, C1-6alkylsulfonyl, and amino.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 46)

The compound of any one of claims 1-38 and 46, wherein the aryl in R7a is tetrahydronaphthyl, 6,7,8,9-tetrahydro-5H-benzo[7]annulenyl, or indanyl; each of which is optionally substituted with one gem-di-C1-3alkyl or one gem-di-halo.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 46)

The compound of any one of claims 1-38 and 46, wherein R7a is unsubstituted 6,7,8,9-tetrahydro-5H-benzo[7]annulenyl, unsubstituted
unsubstituted
unsubstituted
or unsubstituted.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein R7a is
where X3 is —O—, —O—C(R7b3)(R7b3)—, —C(R7b3)(R7b3)—O—, —C(R7b3)(R7b3)—, —C(R7b3)(R7b3)—C(R7b4)(R7b4)—, or —C(R7b3)(R7b3)—C(R7b4)(R7b4)—C(R7b5)(R7b5)—and each R7b1, R7b2, R7b3, R7b4, and R7b5 is independently hydrogen, halo, or C1-3-alkyl.

### Claim 51 (depends on 50)

The compound of claim 50 wherein a) one R7b1 is methyl or ethyl and the other R7b1 is hydrogen, or b) the two R7b1 are both hydrogen, or c) the two R7b1 are both methyl; and each R7b2, R7b3, R7b4, and R7b5 are hydrogen.

### Claim 52 (depends on 50, 51)

The compound of claim 50 or 51, wherein X3 is —C(R7b3)(R7b3)—O—.

### Claim 53 (depends on 50, 51)

The compound of claim 50 or 51, wherein X3 is —C(R7b3)(R7b3)—C(R7b4)(R7b4)—.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38 where R7a is

### Claim 55 (depends on 54)

The compound of claim 54 where R7a is

### Claim 56 (depends on 54, 55)

The compound of claim 54 or 55, wherein a) one R7b is methyl or ethyl and the other R7b is hydrogen, b) the two R7b are both hydrogen, or c) the two R7b are both methyl.

### Claim 57 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, or combinations thereof, selected from the group consisting of:

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A pharmaceutical composition comprising the compound of any one of claims 1-57 and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58, wherein the composition is an oral or injectable composition.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the injectable composition is a subcutaneously injectable composition.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A method for the treatment of a condition associated with voltage-gated sodium channel function in a mammal, comprising the administration of a therapeutically or prophylactically effective amount of the compound of any one of claims 1-57 or the pharmaceutical composition of any one of claims 58-60.

### Claim 62 (depends on 61)

The method of claim 61, wherein the mammal is a human.

### Claim 63 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is pain or wherein the condition is associated with pain.

### Claim 64 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is pain.

### Claim 65 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is associated with pain.

### Claim 66 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is selected from the group consisting of erythromelalgia, diabetic peripheral neuropathy, paroxysmal extreme pain disorder, complex regional pain syndrome, trigeminal neuralgia, multiple sclerosis, osteoarthritis, postherpetic neuralgia, cancer pain, cluster headache, migraine, sciatica, endometriosis, fibromyalgia, and postsurgical pain.

### Claim 67 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is selected from the group consisting of epilepsy, Parkinson's disease, a mood disorder, psychosis, amyotropic lateral sclerosis, glaucoma, ischemia, a spasticity disorder, and obsessive compulsive disorder.

### Claim 68 (depends on 61, 62)

The method of claim 61 or 62, wherein the condition is pain and the pain is nociceptive pain.

### Claim 69

A compound of Formula (X)
or a salt thereof,
wherein
PG1 is a nitrogen-protecting group;
PG2 is a nitrogen-protecting group;
X2 is halo, CN, or N3;
R2 is —NR7C(O)R7a;
R7 is hydrogen or C1-6alkyl;
R7a is aryl optionally substituted with 1, 2, 3, or 4 R7b; heterocyclic optionally substituted with 1, 2, 3, or 4 R7b; or biphenyl optionally substituted with 1, 2, 3, or 4 R7b; and
each R7b, when present, is independently halo, C1-6alkyl, halo-C1-6alkyl, aryl-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, aryloxy, nitro, C1-6alkylthio, halo-C1-6alkylthio, C1-6alkylsulfinyl, halo-C1-6alkylsulfinyl, C1-6alkylsulfonyl, halo-C1-6alkylsulfonyl, amino, C1-6alkylamino, di-C1-6alkylamino, —C(O)(heterocycloalkyl), phenyl, or cyano; where the aryl in aryloxy and aryl-C1-6alkyl are optionally substituted with 1, 2, or 3 groups independently selected from C1-6alkyl, halo, and halo-C1-6alkyl.

### Claim 70 (depends on 69)

The compound of claim 69, wherein PG1 is Tces and PG2 is Troc.

### Claim 71

A method of preparing a compound of Formula (I) comprising
a) in a single step, deprotecting and reducing a compound of Formula (X-1)
to obtain a compound of Formula (X-2):
or a salt thereof;
b) coupling the compound of Formula (X-2) with a compound of Formula X4-LG to obtain a compound of Formula I; wherein
PG1 is a nitrogen-protecting group;
PG2 is a nitrogen-protecting group;
X4 is —C(═O)R4a, —S(O)2R5a, —C(O)NR6aR6b, or —C(O)OR5a;
LG is a leaving group selected from the group consisting of halo,
where represents the point of attachment of LG to X4;
R2 is —NR7C(O)R7a;
R4a is hydrogen; C1-6alkyl; halo-C1-6alkyl; amino-C1-6alkyl; C1-6alkylaminoC1-6alkyl;
di-C1-6alkylaminoC1-6alkyl; C1-6alkoxyC1-6alkyl; cycloalkyl; cycloalkylalkyl; aryl optionally substituted with 1, 2, 3, or 4 R4b groups; aralkyl where the aryl portion is optionally substituted with 1, 2, 3, or 4 R4b groups; heterocycloalkyl optionally substituted with 1, 2, 3, or 4 R4b groups; heteroaryl optionally substituted with 1, 2, 3, or 4 R4b groups; heteroaralkyl where the heteroaryl portion is optionally substituted with 1, 2, 3, or 4 R4b groups; heterocyclic optionally substituted with 1, 2, 3, or 4 R4b groups; or heterocyclicalkyl optionally substituted with 1, 2, 3, or 4 R4b groups;
each R4b, when present, is independently C1-6alkyl, hydroxy, halo, halo-C1-6alkyl, hydroxy-C1-6alkyl, C1-6alkoxy, cyano, phenyl, or —O—(C1-6alkylene)-OZ, wherein Z is hydrogen or
wherein Y is hydrogen or Boc group, and represents the point of attachment;
R5a is heterocycloalkyl, amino, C1-6alkylamino, or di-C1-6alkylamino;
R6a is hydrogen, or C1-6alkyl;
R6b is hydrogen, C1-6alkyl, C1-6alkoxy or cycloalkyl;
R8a is hydrogen, C1-6alkyl, cycloalkyl or phenyl;
R7 is hydrogen or C1-6alkyl;
R7a is aryl optionally substituted with 1, 2, 3, or 4 R7b; heterocyclic optionally substituted with 1, 2, 3, or 4 R7b; or biphenyl optionally substituted with 1, 2, 3, or 4 R7b; and
each R7b, when present, is independently halo, C1-6alkyl, halo-C1-6alkyl, aryl-C1-6alkyl, hydroxy, C1-6alkoxy, halo-C1-6alkoxy, aryloxy, nitro, C1-6alkylthio, halo-C1-6alkylthio, C1-6alkylsulfinyl, halo-C1-6alkylsulfinyl, C1-6alkylsulfonyl, halo-C1-6alkylsulfonyl, amino, C1-6alkylamino, di-C1-6alkylamino, —C(O)(heterocycloalkyl), phenyl, or cyano; where the aryl in aryloxy and aryl-C1-6alkyl are optionally substituted with 1, 2, or 3 groups independently selected from C1-6alkyl, halo, and halo-C1-6alkyl;
to yield a compound of Formula I; and
c) optionally isolating the compound of Formula I.
